Clinical Trial Phases

Data Collection Tools and eCRFs in Phase 3 Clinical Trials: Best Practices and Regulatory Insights

Posted on digi By digi

Phase 3 clinical trials generate enormous volumes of clinical data from thousands of participants, across dozens of study sites, and over long durations. Capturing, cleaning, and analyzing this data efficiently is critical for trial success. Electronic Case Report Forms (eCRFs) and modern data collection platforms form the backbone of digital clinical trial management today.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials

Posted on digi By digi

Phase 1 clinical trials aim to evaluate the safety, tolerability, and pharmacokinetics of investigational products, especially in first-in-human (FIH) settings. One of the most critical aspects of early-phase trial design is the implementation of stopping rules and Dose Limiting Toxicity (DLT) criteria. These safety mechanisms ensure that trials are halted or adjusted when adverse events (AEs) suggest that further exposure at a given dose is unethical or potentially harmful.
Click to read the full article.

Phase 1 (Safety and Dosage)

Use of Patient Registries in Phase 4 Research: Design, Implementation, and Insights

Posted on digi By digi

Patient registries are organized systems that collect uniform data on patients who share a particular condition, exposure, or treatment. In Phase 4 clinical trials, registries play a critical role in monitoring long-term safety, tracking real-world effectiveness, and informing healthcare policy and regulatory decisions.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Role of DSMBs and Ethics Committees in Phase 2 Trials

Posted on digi By digi

As investigational drugs progress into Phase 2 clinical trials, they are tested in larger patient populations and often for longer periods. This increases both the complexity and the ethical responsibilities of clinical research. To ensure participant safety, scientific validity, and regulatory compliance, Data and Safety Monitoring Boards (DSMBs) and Ethics Committees (ECs) or Institutional Review Boards (IRBs) play key oversight roles. This tutorial explores how DSMBs and Ethics Committees function, their differences, and how they collectively contribute to protecting trial integrity and human subjects in Phase 2 research.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Risk-Based Monitoring in Phase 3 Clinical Trials: Methods, Tools, and Best Practices

Posted on digi By digi

Risk-Based Monitoring (RBM) is a modern approach to clinical trial oversight that focuses on identifying, assessing, and mitigating the risks that could impact data quality, subject safety, and trial integrity. Unlike traditional 100% Source Data Verification (SDV), RBM uses a mix of centralized, remote, and targeted monitoring strategies based on real-time risk indicators.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

PK and PD Sampling Strategies in Phase 1: What to Measure and When

Posted on digi By digi

One of the most important goals of Phase 1 clinical trials is to understand how a new drug behaves in the human body. This is achieved by studying pharmacokinetics (PK) and pharmacodynamics (PD). An effective PK/PD sampling strategy ensures robust data generation to support safety, dose escalation, and future trial design. In this tutorial, we explore what to measure, when to collect samples, and how to align with regulatory and scientific expectations.
Click to read the full article.

Phase 1 (Safety and Dosage)

Off-Label Use Monitoring in Phase 4 Clinical Trials: Ensuring Safety and Compliance

Posted on digi By digi

Off-label use refers to the prescription of an approved drug for an indication, dosage, route of administration, or patient population that is not specifically listed in the product’s regulatory label. While legal in most jurisdictions, such use presents potential risks—especially when safety or efficacy data for the new use is limited.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Handling Adverse Events and Serious Adverse Events (SAEs)

Posted on digi By digi

Adverse events (AEs) and serious adverse events (SAEs) are a core focus of safety monitoring in clinical trials, particularly in Phase 2 where investigational drugs are administered to patients with the target condition. The proper handling, documentation, and reporting of these events are not only critical for patient safety but also regulatory compliance and overall trial success. This tutorial provides a comprehensive guide on the processes, roles, and best practices for managing AEs and SAEs in Phase 2 clinical studies.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Interim Analysis in Phase 3 Trials: Planning, Execution, and Regulatory Guidance

Posted on digi By digi

Interim analysis refers to the planned evaluation of clinical trial data at specific timepoints before the trial is completed. In Phase 3 trials, which often span years and involve large patient populations, interim analyses help sponsors and stakeholders make informed decisions about efficacy, safety, futility, or operational adjustments.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Analyzing Phase 1 Pharmacokinetics: From Sample to Report

Posted on digi By digi

Pharmacokinetic (PK) analysis is a fundamental component of Phase 1 clinical trials. It provides insight into how a drug is absorbed, distributed, metabolized, and eliminated in humans. This data is essential for determining safe and effective dosing regimens. In this tutorial, we walk through the complete PK workflow—from sample collection to final reporting—to help clinical researchers, analysts, and sponsors understand how to generate reliable and compliant PK data.
Click to read the full article.

Phase 1 (Safety and Dosage)